Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

5.15USD
26 Apr 2018
Change (% chg)

$0.15 (+3.00%)
Prev Close
$5.00
Open
$5.00
Day's High
$5.20
Day's Low
$5.00
Volume
4,778
Avg. Vol
12,120
52-wk High
$5.75
52-wk Low
$2.15

Select another date:

Wed, Mar 7 2018

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

BRIEF-Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank

* XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING

BRIEF-Xenon Pharmaceuticals reports Q3 loss per share $0.43

* Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

Select another date: